[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
Views 306
Citations 0
Correction
November 19, 2019

Clarifying Terminology Use

JAMA. 2019;322(19):1925. doi:10.1001/jama.2019.17982

In the Viewpoint entitled “Evolving Issues in the Treatment of Depression”1 published in the June 25, 2019, issue of JAMA, clarification was needed regarding the use of the terms “ketamine” and “esketamine.” In the section titled “Ketamine,” the first sentence of the first paragraph should have read “On March 5, 2019, the Food and Drug Administration approved nasal esketamine (the s-enantiomer of ketamine) (Spravato), in conjunction with an oral antidepressant in adults, as a drug for treatment-resistant depression (TRD).” The first sentence in the third paragraph of that section should have read “Clinical trials have established that more than half of the patients with TRD experience antidepressant effect of intranasal ketamine and esketamine or intravenous ketamine in addition to their treatment as usual.” And the third sentence of the third paragraph in that same section should have read “Ketamine and esketamine represent promising drugs that potentially can help alleviate TRD, but further studies are necessary to identify which patients will receive sustained benefit.” This article was corrected online.

References
1.
Köhler-Forsberg  O, Cusin  C, Nierenberg  AA.  Evolving issues in the treatment of depression.  JAMA. 2019;321(24):2401-2402. doi:10.1001/jama.2019.4990PubMedGoogle ScholarCrossref
×